XJPX4888
Market cap93mUSD
Jan 23, Last price
477.00JPY
1D
-1.24%
1Q
3.47%
IPO
-33.84%
Name
Stella Pharma Corp
Chart & Performance
P/E
—
P/S
54.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
269m
+17.65%
Net income
-764m
L-1.94%
CFO
-877m
L+5.94%
Profile
Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 269,491 17.65% | 229,067 128.85% | 100,096 -51.40% | ||
Cost of revenue | 445,193 | 396,123 | 270,238 | ||
Unusual Expense (Income) | |||||
NOPBT | (175,702) | (167,056) | (170,142) | ||
NOPBT Margin | |||||
Operating Taxes | 2,772 | 2,850 | 3,630 | ||
Tax Rate | |||||
NOPAT | (178,474) | (169,906) | (173,772) | ||
Net income | (763,749) -1.94% | (778,824) 1.45% | (767,719) 16.45% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 388,258 | 438,294 | 3,616,623 | ||
BB yield | -4.34% | -3.92% | -21.36% | ||
| Debt | |||||
Debt current | 160,008 | 160,008 | 160,008 | ||
Long-term debt | 773,292 | 933,300 | 1,093,308 | ||
Deferred revenue | |||||
Other long-term liabilities | 214,718 | 221,667 | 237,633 | ||
Net debt | (1,420,347) | (1,987,993) | (2,404,885) | ||
| Cash flow | |||||
Cash from operating activities | (876,837) | (827,669) | (1,081,129) | ||
CAPEX | (10,978) | (29,329) | (46,262) | ||
Cash from investing activities | (9,010) | (29,925) | (350,562) | ||
Cash from financing activities | 228,353 | 291,819 | 3,829,240 | ||
FCF | (326,304) | (250,706) | (547,737) | ||
| Balance | |||||
Cash | 2,353,647 | 2,710,301 | 3,276,201 | ||
Long term investments | 371,000 | 382,000 | |||
Excess cash | 2,340,172 | 3,069,848 | 3,653,196 | ||
Stockholders' equity | 2,181,320 | 2,531,593 | 1,171,346 | ||
Invested Capital | 1,343,711 | 1,529,553 | 3,371,096 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 30,975 | 28,877 | 28,083 | ||
Price | 289.00 -25.32% | 387.00 -35.82% | 603.00 | ||
Market cap | 8,951,864 -19.90% | 11,175,469 -34.01% | 16,934,063 | ||
EV | 7,531,517 | 9,187,476 | 14,530,178 | ||
EBITDA | (140,663) | (132,007) | (136,010) | ||
EV/EBITDA | |||||
Interest | 2,084 | 2,580 | 3,100 | ||
Interest/NOPBT | |||||